相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
Zijie Cai et al.
SCIENCE CHINA-LIFE SCIENCES (2023)
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Gene regulation by long non-coding RNAs and its biological functions
Luisa Statello et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2021)
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
Man-Fung Yuen et al.
NATURE MEDICINE (2021)
Antisense technology: an overview and prospectus
Stanley T. Crooke et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Cyclin E in normal physiology and disease states
Chen Chu et al.
TRENDS IN CELL BIOLOGY (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?
Meenakshi Anurag et al.
CLINICAL CANCER RESEARCH (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Jonathan Chou et al.
CANCER DISCOVERY (2020)
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Timothy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
Qianfeng Shi et al.
NATURE COMMUNICATIONS (2020)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long Noncoding RNA HCP5, a Hybrid HLA Class I Endogenous Retroviral Gene: Structure, Expression, and Disease Associations
Jerzy K. Kulski
CELLS (2019)
Transcription regulation by the Mediator complex
Julie Soutourina
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
M. Arnedos et al.
ANNALS OF ONCOLOGY (2018)
Long Noncoding RNA in Cancer: Wiring Signaling Circuitry
Chunru Lin et al.
TRENDS IN CELL BIOLOGY (2018)
Genome-wide Estrogen Receptor-alpha activation is sustained, not cyclical
Andrew N. Holding et al.
ELIFE (2018)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan et al.
NATURE COMMUNICATIONS (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I
Rodrigo Pena-Hernandez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages
Antonio Adamo et al.
NATURE GENETICS (2015)
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer
Pascal Jezequel et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
C. Elizabeth Caldon et al.
MOLECULAR CANCER THERAPEUTICS (2012)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
FOXA1 is a key determinant of estrogen receptor function and endocrine response
Antoni Hurtado et al.
NATURE GENETICS (2011)
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
Maurizio Scaltriti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
CTCF: Master Weaver of the Genome
Jennifer E. Phillips et al.
CELL (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen et al.
NATURE REVIEWS CANCER (2008)
Cyclin E in normal and neoplastic cell cycles
HC Hwang et al.
ONCOGENE (2005)
A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry
Y Matsumoto et al.
SCIENCE (2004)
Cyclin E and survival in patients with breast cancer.
K Keyomarsi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase
DM Koepp et al.
SCIENCE (2001)
Antisense therapy in oncology:: new hope for an old idea?
I Tamm et al.
LANCET (2001)
分享论文
